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Statin (HMG-CoA reductase inhibitors) therapy has
favorable impacts in reducing cardiovascular mortality
in major clinical trials [1,2]. Beyond lipid lowering and
pleiotropic effects, it has been suggested that statins
decrease mortality by reducing life-threatening ven-
tricular arrhythmia [3,4]. A previous study indicated
that hypercholesterolemia per se was associated with
electrophysiologic remodeling and increased vulner-
ability to ventricular fibrillation in an animal model
[5]. Recently, hypercholesterolemia was found to be
associated with altered ventricular repolarization [6].
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Emerging evidence suggests that statins have a favorable impact on the reduction of arrhythmia
events and sudden cardiac death in patients with structural heart disease. We aimed to investigate
the possibly and directly favorable effects of statins on ventricular late potentials, QT dispersion,
and transmural dispersion of repolarization attained by analyzing clinical electrocardiography
(ECG) risk stratification parameters in patients with hypercholesterolemia without structural heart
disease. In total, 82 patients (45 females; mean age, 62±10 years) with hypercholesterolemia were
enrolled in this prospective study to examine the effects of statin therapy (atorvastatin 10 mg/day
for 3 months) on ECG risk stratification parameters. Surface 12-lead ECG and signal-average
ECG (SAECG) were recorded before and after statin treatment. The SAECG parameters, QT dis-
persion, Bazett-corrected QT (QTc) dispersion, T wave peak-to-end interval (Tpe), and percentage
of Tpe/QT interval were calculated and compared before and after statin therapy. Twelve-lead
ambulatory 24-hour ECGs were recorded in 12 patients. The results demonstrated that after statin
therapy for 3 months, serum levels of total cholesterol and low-density lipoprotein cholesterol were
significantly reduced (both p values < 0.001). However, neither significant changes of each SAECG
parameter nor the frequency of late potentials were demonstrated after atorvastatin therapy. In
addition, no significant changes in QT dispersion, QTc dispersion, Tpe, or Tpe/QT were found.
However, 24-hour ambulatory ECG revealed a flattening effect of circadian variation of QTc dis-
persion after atorvastatin therapy. In conclusion, the favorable antiarrhythmia effect of atorva-
statin (10 mg/day) therapy cannot be directly reflected by analyzing these noninvasive ECG risk
stratification parameters in low-risk patients with hypercholesterolemia.
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Evidence of antiarrhythmic effects after statin therapy
has been explored in different patient populations,
including patients with acute myocardial infarc-
tion, patients receiving implantable cardioverter-
defibrillator therapy, and patients with symptomatic
extrasystolic activity [7–10]. This antiarrhythmic effect
was postulated as a new pleiotropic effect of statin
therapy [11]. 
Several noninvasive surface electrocardiography
(ECG) tools including signal-average ECG (SAECG)
and QT dispersion have been used to identify ven-
tricular electrical abnormalities for arrhythmic risk
stratification [12,13]. The transmural dispersion of ven-
tricular repolarization was suggested to be reflected in
the duration of T wave peak-to-end interval (Tpe) on
surface ECG and analysis of Tpe was suggested as a
new index of the risk of ventricular arrhythmia [14,15].
Although the antiarrhythmic effects of statin therapy
were evaluated with late potentials from SAECG and
QT dispersion from surface 12-lead ECG [7,10,11], the
results remain controversial [16]. Furthermore, effects
of statin therapy on the Tpe interval remain unknown.
The aim of this study is to investigate the direct
electrocardiographic evidences of antiarrhythmic ef-
fects after statin therapy by ECG risk stratification tools
in patients with hypercholesterolemia.
METHODS
Patients
A total of 82 patients with hypercholesterolemia (total
cholesterol ≥ 200 mg/dL or low-density lipoprotein
[LDL] cholesterol ≥160 mg/dL) at an outpatient clinic
were enrolled in this prospective clinical study be-
tween December 2003 and July 2005. Patients were
excluded if they had evidence of renal or hepatic dis-
ease, severe hypertriglyceridemia, anemia, acute ill-
ness, leukocytosis (white blood cell count > 10,000),
thrombocytosis (platelet count > 450,000), chronic in-
flammatory diseases, New York Heart Association class
III or IV congestive heart failure, history of myocar-
dial infarction, mitral valve prolapse, right or left bun-
dle branch block, use of psychotropic drugs (which
may affect the QT interval) or antiarrhythmic drugs
(except β-blockers), blood pressure > 180 mmHg (sys-
tolic) or > 110 mmHg (diastolic), positive history of
drug or alcohol abuse, current use of any medication
known or suspected to inhibit or induce the cytochrome
P450 3A enzyme system. The protocol for this study
was approved by the Institutional Review Board at
Kaohsiung Medical University and written informed
consent was obtained from all patients.
Study design
After a 4-week washout period for any lipid-lowering
therapy undertaken prior to the study, patients took
atorvastatin 10mg/day for 3 consecutive months. Con-
comitant therapies for other illnesses were given and
maintained during the entire study. At baseline and
again after the end of treatment, lipid profiles after a
12-hour fast, surface ECGs, and SAECG recordings
were obtained between 8 and 10 am. Twelve-lead am-
bulatory 24-hour ECGs were recorded in 12 patients
both before and after atorvastatin treatment. Com-
pliance was monitored in weeks 4, 8, and 12.
SAECG
The time-domain SAECG recordings were performed
using a high-resolution electrocardiograph (1200 EPX,
Arrhythmia Research Technology, Austin, TX, USA)
in accordance with the recommended standards for
analysis of ventricular late potentials on SAECG [16].
The signal-averaging process was performed by using
three standard orthogonal bipolar X, Y, and Z leads in
supine position in each patient. About 400 QRS com-
plexes were amplified, averaged, and filtered with a
40-Hz high-pass filter, and combined into a vector
magnitude X2 + Y2 + Z2 according to the method de-
scribed by Gomes et al [17]. Significant efforts were
made to limit the noise level to under 0.5 μV during
all recordings. The onset and offset of the QRS com-
plex were determined by an algorithm that calculates
the filtered QRS duration (QRSd), the root-mean-square
voltage of the last 40 ms (RMS 40) of the QRS com-
plex, and the duration of the terminal low (< 40 μV)
amplitude signals (LAS 40) of the QRS complex. Late
potentials were considered to be present, if the SAECG
met two of the three of the following Gomes criteria:
filtered QRS duration >114 ms; RMS 40<20μV; or LAS
40 > 38 ms [17,18].
QT dispersion
The duration of QT interval was measured at each lead
of the standard 12-lead surface ECG according to
Perkiomaki et al [19]. QT interval was measured from
the onset of the Q wave to the return of the T wave at
the isoelectric line. If a large U wave was present, the
end of the T wave was taken at the intersection of the
tangent to the repolarization slope with the isoelec-
tric line. If T wave < 0.1 mV in amplitude, then it was
excluded. QT dispersion was calculated by subtracting
the shortest QT from the longest QT in absolute value
(QTmax −QTmin). Bazett’s formula (QTc=QT/√RR) was
used to obtain QT interval corrected for the heart rate
[20]. All measurements were made by two observers
blinded to the experimental design.
Transmural dispersion of repolarization
The interval of Tpe and Bazett-corrected Tpe (Tpec)
was obtained from a digitized V5 lead in surface 12-
lead ECG before and after atorvastatin therapy in each
patient [21]. The peak of the T wave was defined as
the peak of the parabola with the highest-amplitude
change after the QRS complex. The end of the T wave
was defined as the point at which the steepest tangent
after the T wave apex and the baseline cross. Only up-
right monophasic T waves were measured and the low-
amplitude T waves < 0.1 mV were excluded. The data
were expressed as the absolute interval in milliseconds
as well as relative to the QT interval (Tpe/QT × 100%).
Ambulatory 24-hour ECG
Twelve-lead ambulatory 24-hour ECGs (Rozinn Elec-
tronics, NY, USA) were performed in 12 patients before
and after statin therapy to look for circadian changes
in QT and QTc dispersion and in Tpe [22]. The data
were analyzed on a computer screen and the QT inter-
val as well as the Tpe were measured manually at a
screen rate of 50 mm/s using an on-screen caliper am-
plified at two times the voltage. The intervals of QT
dispersion calculated from the 12-lead ambulatory
ECG and Tpe calculated from digitized lead V5 were
measured every hour. There were at least 21 data points
available for each patient in a 24-hour recording. The
circadian changes in QT dispersion, QTc dispersion,
Tpe, and Tpe/QT were analyzed and compared before
and after statin therapy [22].
Statistical analysis
All data are expressed as mean ± SD. Continuous
variables were tested for normal distribution with
Kolmogorov–Smirnov test and compared by means
of paired student’s t test before and after statin therapy.
In cases of non-normal distribution, nonparametric
methods were used (Mann-Whitney U test or Wilcoxon
signed rank test). Correlations were determined using
Pearson’s correlation test and Spearman’s rank order
correlation test. Changes in the frequency of ventricu-
lar late potential on SAECG before and after atorvas-
tatin therapy were compared using McNemar test.
The differences in 24-hour ambulatory recordings
were evaluated by a one-way repeated-measurement
ANOVA followed by the appropriate post hoc test. 
A p value < 0.05 was considered statistically signifi-
cant. All reported p values are two tailed and all con-
fidence intervals were computed at the 95% level.
Statistical analysis was performed with SPSS version
11.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Changes in lipid profiles
Baseline characteristics of the 82 patients in this study
are summarized in Table 1. Diabetes and hypertension
were present in 16 (19%) and 25 (30%) patients, respec-
tively. The changes in lipid profiles after statin therapy
are shown in Table 2. At baseline, total cholesterol
levels > 300 mg/dL and between 240 and 299 mg/dL
were present in five (6.1%) and 46 (56.1%) patients,
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Table 1. Baseline characteristics of the study population
(n = 82)
Characteristics Value
Age (yr) 62 ± 10
Male/female 37/45
Body mass index (kg/m2) 24 ± 5
Diabetes mellitus, n (%) 16 (19)
Hypertension, n (%) 25 (30)
Cigarette smoking, n (%) 10 (12)
LVEF (%) 62 ± 5
Lipid profiles (mg/dL)
Total cholesterol 248 ± 31
LDL cholesterol 157 ± 36
HDL cholesterol 49 ± 12
Triglycerides 164 ± 131
Concomitant medications, n (%)
Sulfonylurea 15 (18)
Metformin 4 (5)
Aspirin 12 (17)
β-blocker 10 (12)
Calcium antagonist 19 (23)
ACE inhibitor/ARB 31 (37)
LVEF = left ventricular ejection fraction; LDL = low-density
lipoprotein; HDL = high-density lipoprotein; ACE = angiotensin
converting enzyme; ARB = angiotensin receptor blocker.
respectively. LDL cholesterol levels > 200 mg/dL and
between 160 and 199 mg/dL were present in seven
(8.5%) and 29 (35.4%) patients, respectively. After ator-
vastatin 10 mg/day therapy for 3 months, significant
reductions in both total cholesterol (decreased by
22.5%, p < 0.001) and LDL cholesterol (decreased by
28.6%, p < 0.001) levels were demonstrated. No signif-
icant changes were observed in serum levels of HDL
cholesterol or triglycerides.
Changes in SAECG parameters
Results of SAECG parameters at baseline and after
statin therapy are summarized in Table 2 and Figure 1.
No correlations were found between serum levels of
total cholesterol or LDL cholesterol versus each SAECG
parameter at baseline or after statin therapy. At base-
line, there were three (3.6%), 19 (23.2%), and 17 (20.7%)
patients with filtered QRSd > 114 ms, RMS 40 < 20 μV,
and LAS 40 > 38 ms, respectively. After statin therapy
for 3 months, three (3.6%), 14 (17.0%), and 14 (17.0%)
patients demonstrated filtered QRSd > 114 ms, RMS
40 < 20 μV and LAS 40 > 38 ms, respectively. The mean
values of each SAECG parameter before and after
statin therapy did not show significant differences
(all p values > 0.05) (Table 2). Changes in the rates (%)
of patients with positive late potentials before and after
atorvastatin therapy are illustrated in Figure 1. Sixteen
patients had positive late potentials at baseline, of
which eight of them became negative and the other
eight patients remained positive after statin therapy.
Sixty-six patients had negative late potentials at base-
line, of which 61 patients remained negative and the
other five patients became positive after statin therapy.
However, the changes in the rates of positive late poten-
tials before and after statin therapy did not reach sig-
nificant levels (p = 0.581, McNemar test).
Changes in study parameters of 
12-lead surface ECG
Changes in QT dispersion and Tpe calculated from
12-lead surface ECG before and after statin therapy
are summarized in Table 2. No correlations were found
between total cholesterol and LDL cholesterol versus
QT dispersion or QTc dispersion at baseline. The mean
values of QTmax interval, QT dispersion, and QTc dis-
persion were consistently less after statin therapy. How-
ever, the differences in the values of these parameters
before and after statin therapy did not achieve statisti-
cal significance (all p values >0.05) in all subjects (n=82)
or in subgroup analysis for those patients with baseline
QTc > 440 ms (n = 15). The mean values of Tpe, Tpec,
and ratio of Tpe/QT obtained from the digitized V5
lead at baseline were 77±11ms, 70±10ms, and 18±3%,
respectively. No correlations were found between total
and LDL cholesterol level versus Tpe, Tpec, or Tpe/QT
ratio at baseline. After statin therapy, no significant
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Table 2. Summary of lipid profiles and all studied ECG
parameters before and after atorvastatin 10 mg/d for 
3 months (n = 82)*
Parameters Baseline 3 mo p
Lipid profiles (mg/dL)
Total cholesterol 248 ± 31 192 ± 39 < 0.001
LDL cholesterol 157 ± 36 112 ± 36 < 0.001
HDL cholesterol 49 ± 12 47 ± 11 0.238
Triglycerides 164 ± 131 141 ± 94 0.092
SAECG parameters
Total filtered 96 ± 17 95 ± 15 0.155
QRSd (ms)
RMS 40 (μV) 43 ± 29 45 ± 28 0.657
LAS 40 (ms) 31 ± 10 29 ± 10 0.099
Surface 12-lead ECG
Heart rate (bpm) 86 ± 19 83 ± 21 0.956
QTmax interval (ms) 405 ± 39 391 ± 28 0.297
QT dispersion (ms) 46 ± 19 43 ± 18 0.215
QTc dispersion (ms) 42 ± 19 39 ± 18 0.192
Tpe interval (ms) 77 ± 11 75 ± 6 0.317
Tpe/QT (%) 18 ± 3 17 ± 4 0.159
*All data are expressed as mean ± SD. ECG = electrocardiogra-
phy; LDL = low-density lipoprotein; HDL = high-density
lipoprotein; SAECG = signal-average ECG; QRSd = QRS dura-
tion; RMS 40 = root-mean-square voltage of terminal at 40 ms
of QRS complex; LAS 40 = low-amplitude signals; Tpe = T
wave peak-to-end interval.
LP (+)
n = 16
LP (+)
n = 13
LP (−)
n = 66
n = 5 n = 8
n = 8
n = 61
p = 0.581
Baseline Atorvastatin therapy
for 3 mo
LP (−)
n = 69
Figure 1. Effects of atorvastatin therapy on the frequency of ven-
tricular late potentials by signal-averaged ECG analysis in each
patient. No significant difference in frequency of late potentials
between baseline and after statin therapy was demonstrated
(p = 0.581 by McNemar test). LP = late potential.
differences could be demonstrated in the changes of
Tpe, Tpec, and Tpe/QT (all p values > 0.05) in all sub-
jects or in subgroup analysis for those patients with
baseline QTc > 440 ms.
Changes in study parameters of 
24-hour ambulatory ECG
Distribution of QTc dispersion obtained from 24-hour
recordings of 12-lead ambulatory ECGs is displayed in
Figure 2. From the baseline 24-hour QTc dispersion
curve, significant higher and lower QTc dispersion
could be demonstrated in the morning between 8
and 10 am and in the afternoon between 2 and 4 pm,
respectively. After statin therapy, differences in QTc 
dispersion for each hour diminished and became non-
significant. The differences in 24-hour curves of QT
dispersion, Tpe, or Tpe/QT (%) on ambulatory ECG
before and after statin therapy were not statistically
significant.
DISCUSSION
The aim of this study was to evaluate whether the
antiarrhythmic effects conferred by statin therapy
could be demonstrated by use of noninvasive ECG
risk tools including surface 12-lead ECG, SAECG, and
24-hour Holter ECGs. However, almost all the study
parameters failed to exhibit significant changes after
3 months of atorvastatin 10 mg/day treatment, except
for the flattening effect of QTc dispersion on 24-hour
ambulatory ECG during 8–10 am and 2–4 pm, while
serum levels of total and LDL cholesterol were signif-
icantly reduced.
It remained unclear whether statin therapy had
“direct” antiarrhythmic effects. Most of the antiar-
rhythmic benefits after statin therapy observed in
high cardiovascular risk patients might be explained
by statins’ pleiotropic effects, including anti-ischemia,
anti-inflammation, antihypertrophy, and by even
prompting angiogenesis and modulation of sympa-
thetic activation and autonomic dysfunction [3,4,11].
Recently, hypercholesterolemia per se has been reported
to induce proarrhythmic sympathetic neural sprouting
and ventricular electrophysiologic remodeling, and
an increased vulnerability to ventricular fibrillation
in a high-fat-fed animal model [5]. In that study, hy-
percholesterolemic rabbits with serum cholesterol of
2,097±288mg/dL had longer QTc intervals and higher
QTc dispersion than standard rabbits with serum cho-
lesterol of 59 ± 9 mg/dL. The results obtained from
such an extremely high ratio (35.5-fold) of lipid pro-
files were difficult to apply in human beings. Recently,
one clinical study by Szabo et al [6] suggested that
hyperlipidemia may have a direct effect on ventricular
repolarization by demonstrating a positive correlation
between lipid profiles and QT dispersions in type IIb
hyperlipidemic patients without ischemic heart dis-
ease. The mean serum levels of total cholesterol of their
patients were 291 mg/dL, significantly higher than
that of our patients.
No significant change in the frequency of positive
ventricular late potentials on SAECG was demon-
strated after statin treatment in this study. This result
differed from that reported by Kayikcioglu et al [7] 
where patients experienced acute myocardial infarc-
tion while receiving thrombolytic therapy, and treat-
ment with pravastatin 40 mg/day for 10 days reduced
the incidence of ventricular late potentials. Most of the
patients in our study lacked late potentials at baseline
because of their relative low risk of cardiovascular dis-
eases. The difference might result from the different
composites of the subjects of the two studies.
The idea of antiarrhythmic effect as a “new” pleio-
tropic effect in statin therapy was postulated by Mark
and Katona [11]. In their study, treatment with fluva-
statin 40mg/day for 12 months significantly decreased
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Figure 2. Curves of QTc dispersion displayed over 24 hours by
ambulatory 12-lead ECG recordings in 12 patients with hyper-
cholesterolemia at baseline and after atorvastatin therapy. Signi-
ficant differences were found between 8 and 10 am and between 2
and 4 pm in the baseline curve. After statin therapy, the QTc dis-
persion curve became flat and without significant circadian
changes. Data are displayed as mean ± standard error. *p < 0.05.
QT dispersion, though providing only a favorable
trend in QTc dispersion in 23 patients with hypercho-
lesterolemia. Another study by Gualdiero et al [10]
demonstrated that simvastatin 40mg/day for 3 months
significantly reduced QTc dispersion in patients with
isolated hypercholesterolemia and with symptomatic
extrasystolic activity. In this study, the differences in
QTmax interval and QT or QTc dispersion before and
after statin therapy did not achieve statistical signifi-
cance in all subjects or in subgroup analysis for those
patients with baseline QTc >440 ms. Most of our study
patients were free of extrasystolic activity. Furthermore,
the correlations between lipid profiles and QT disper-
sion in our study population were not significant, in
contrast to the results reported by Szabo et al [6]. The
values of serum total cholesterol (291 ± 74 mg/dL)
and LDL cholesterol (187 ± 64 mg/dL) in their study
population were higher compared with those of our
study subjects at baseline. The effect of statin on QT
dispersion might be different, depending on different
levels of lipid profiles before therapy and different
patient populations enrolled.
Effects of statin therapy on the index of transmural
dispersion of repolarization are unknown. The termi-
nal portion of the T wave was suggested to reflect the
disparity of action potential duration among mid-
myocardial M cell, epicardial and endocardial cells
[15]. In our study, Tpe, Tpec, and the Tpe/QT ratio
showed no significant change after atorvastatin treat-
ment 10 mg/day for 3 months. These parameters have
been reported by Yamaguchi et al [21] as predictors of
torsade de pointes in patients with acquired long QT
syndrome. They defined that a Tpe/QT ratio >28% was
a good cut-off point for predicting the occurrence of
torsade de pointes. Both before and after atorvastatin
therapy, the values of Tpe/QT in our study were < 28%
and did not show significant changes. Results from
this study suggest that in patients with isolated hyper-
cholesterolemia and without significant organic heart
disease, the transmural dispersion of ventricular repo-
larization is not significantly prolonged and is not
affected by statin therapy.
In our study, 12-lead ambulatory 24-hour ECGs
were analyzed in 12 patients. From these 12-lead Holter
ECG recordings, we can calculate the changes in QT
dispersion at any hour or minute and can analyze the
circadian variation in the QT dispersion more thor-
oughly. Before statin therapy, a circadian variation in
QTc dispersion was seen between 8–10 am in the
morning and 2–4 pm in the afternoon, which was
comparable with previous reports showing that QT
dispersion may possess circadian variation during a
day [22–24]. However, after 3 months of atorvastatin
treatment, the hourly QTc variation diminished and
the 24-hour QTc dispersion curve flattened. Liu et al
[5] reported that sympathetic hyperinnervation and
nerve sprouting remodeling could be demonstrated
in their hypercholesterolemic rabbits with increased
vulnerability to ventricular fibrillation. Molnar et al
[23] postulated that the phenomenon of QTc variabil-
ity reaching a peak shortly after awakening might be
associated with increased autonomic instability and
vulnerability to ventricular tachycardia or sudden car-
diac death. Accordingly, reduction in the fluctuation of
repolarization dispersion after atorvastatin therapy in
the present study might be postulated as one possible
antiarrhythmic effect that goes against the morning
surge of arrhythmic events reported [24]. Further study
with a larger sample size is warranted to investigate
statin therapy with its possible antiarrhythmic efficacy
in terms of circadian variation and autonomic regula-
tion of these repolarization parameters.
Study limitations
Several limitations of this study should be mentioned.
First, in this prospective clinical study, patients with
hypercholesterolemia were enrolled for atorvastatin
10 mg/day treatment. Effects of higher doses of ator-
vastatin were not studied. Nevertheless, atorvastatin
10 mg/day in our study achieved therapeutic reduc-
tion in total and LDL cholesterol levels. Second, the
number of patients in our study was relatively small
and the treatment period was limited to 3 months. The
differences in ventricular late potential, QT dispersion,
or Tpe might change if the number of patients tested
was increased or the study duration prolonged. Third,
the subjects enrolled in our study were patients with
relatively low cardiovascular risk. It was our aim to
purely evaluate the magnitude of possible antiarrhyth-
mia effects of atorvastatin therapy by ECG analysis
in these low-risk hypercholesterolemia patients who
were eligible for statin therapy but without signifi-
cant structural heart disease. Results from this study
might be different from those obtained from high-risk
hypercholesterolemia patients with significant organic
heart diseases and history of sudden cardiac death [16].
In conclusion, no significant effects of statin ther-
apy on SAECG parameters, QT dispersion, and Tpe
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were demonstrated, except for a flattening of the circa-
dian variation of QTc dispersion on 24-hour ambula-
tory ECG between 8–10 am and 2–4 pm, while serum
levels of total and LDL cholesterol were significantly
reduced. The favorable impact on cardiovascular mor-
bidity and mortality by statin therapy is not directly
reflected in these ECG risk-stratification parameters
in patients with hypercholesterolemia.
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